Conversion from preclinical to dinical stage of Alzheimer's disease as shown by decline of cognitive function in carriers of the Swedish APP-mutation.
The characterisation of the borderline syndrome between normal cognitive function and Alzheimer's disease (AD), often mentioned as Mild Cognitive Impairment (MCI) has been a goal for recent research. However, a variety of definitions of MCI-like syndromes and the uncertainty about the final diagnosis have hampered progress. To overcome these problems, the present study will describe cognitive function in two healthy mutation carriers and two matched non-carriers of the Swedish double mutation family, during the time period when carriers convert to a symptomatic stage, i.e., true preclinical AD, and finally into the stage when a clinical diagnosis of AD is first possible. The findings question the generality of common MCI concepts and the commonly held beliefs about cognitive features in late preclinical stage of AD.
Almkvist
O
O
Division of Geriatric Medicine, Karolinska Institutet, Department of Clinical Neuroscience, Occupational Therapy, and Elderly Care Research (NEUROTEC), Huddinge University Hospital, Stockholm, Sweden. ove.almkvist@neurotec.ki.se
Axelman
K
K
Basun
H
H
Wahlund
L O
LO
Lannfelt
L
L
D000544:Alzheimer Disease / Q000175:diagnosis / Q000235:genetics* / Q000503:physiopathology*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D003072:Cognition Disorders / Q000175:diagnosis / Q000235:genetics* / Q000503:physiopathology*; D018450:Disease Progression; D006304:Health Status; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D009483:Neuropsychological Tests; D013548:Sweden
D016564:Amyloid beta-Protein Precursor